Profile · INSIDERData sourcesSEC Form 417m ago
House PTR17m ago
SEC 13F17m ago
Robinhood Chain17m ago
Public companyANAVEX LIFE SCIENCES CORP.
AVXLCIK 0001314052
Price$1.15
1 year-84.3%
Disclosed transactions10
Buys / sells0 / 0
Max Insider Score15
Connections with evidence8
AVXL · disclosed activity on price
| Score | Actor | Security | Side | Value | Executed | Disclosed | Lag | Source | Evidence |
|---|
| 15 | DODonhauser Peter D.O.Director | AVXLANAVEX LIFE SCIENCES CORP. Grant or award | A | — 50.0K sh | Nov 3, 2026 | Nov 6, 2026 |
| 15 | VVVelden Claus VanderDirector | AVXLANAVEX LIFE SCIENCES CORP. Grant or award | A | — 50.0K sh | Nov 3, 2026 | Nov 6, 2026 traded Nov 3, 2026 | +3d | SEC Form 4 | |
| 15 | KTKellmeyer TerrieDirector, President and CEO | AVXLANAVEX LIFE SCIENCES CORP. Grant or award | A | — 200.0K sh | Nov 3, 2026 | Nov 6, 2026 traded Nov 3, 2026 | +3d | SEC Form 4 | |
| 15 | | AVXLANAVEX LIFE SCIENCES CORP. Grant or award | A | — 50.0K sh | Nov 3, 2026 | Nov 6, 2026 traded Nov 3, 2026 | +3d | SEC Form 4 | |
| 9 | BSBoenisch SandraPFO & Treasurer | AVXLANAVEX LIFE SCIENCES CORP. Grant or award | A | — 25.0K sh | Sep 24, 2026 | Sep 28, 2026 traded Sep 24, 2026 | +4d | SEC Form 4 | |
| 9 | BSBoenisch SandraPFO & Treasurer | AVXLANAVEX LIFE SCIENCES CORP. Grant or award | A | — 20.0K sh | Sep 24, 2026 | Sep 28, 2026 traded Sep 24, 2026 | +4d | SEC Form 4 | |
| 9 | BSBoenisch SandraPFO & Treasurer | AVXLANAVEX LIFE SCIENCES CORP. Grant or award | A | — 25.0K sh | Sep 24, 2026 | Sep 28, 2026 traded Sep 24, 2026 | +4d | SEC Form 4 | |
| 9 | BSBoenisch SandraPFO & Treasurer | AVXLANAVEX LIFE SCIENCES CORP. Grant or award | A | — 25.0K sh | Sep 24, 2026 | Sep 28, 2026 traded Sep 24, 2026 | +4d | SEC Form 4 | |
| 15 | MUMissling Christopher UDirector, President and CEO | AVXLANAVEX LIFE SCIENCES CORP. Grant or award | A | — 125.0K sh | Jan 6, 2026 | Jan 9, 2026 traded Jan 6, 2026 | +3d | SEC Form 4 | |
| 15 | BSBoenisch SandraPFO & Treasurer | AVXLANAVEX LIFE SCIENCES CORP. Grant or award | A | — 12.5K sh | Jan 6, 2026 | Jan 9, 2026 traded Jan 6, 2026 | +3d | SEC Form 4 | |
SEC SIC 2836 · Biological Products, (No Diagnostic Substances) · Nov 4, 2026
FORBES-TATELDA Q1 2026 first quarter · Health issues · Aug 26, 2026